BIO-Europe Spring® 2012 produced by EBD Group, the leading partnering firm for the life science industry, will be held in Amsterdam March 19–21, 2012 at the Amsterdam RAI Convention Center. The event will highlight the biotech and pharmaceutical community in the Netherlands, with a special emphasis on recent Dutch biotech deals and the power alliances that made them happen.
The conference program features a Monday morning workshop entitled “Close up and personal: Recent deals examined from both sides” moderated by Roel Bulthuis, Head of Merck Serono Ventures, that includes panelists Willem van Weperen of to-BBB technologies; Onno van de Stolpe of Galapagos; Rudy Mareel of Synthon; and Vincent de Groot of Synthon. Other deal-centric panels include one on examining major deals of the past year and another on strategies for overcoming the challenges of late state deals.
“The Netherlands is an ideal place for dealmaking and partnering opportunities due to its strong life sciences cluster and growth potential,” said Carola Schropp, President, EBD Group. “The Netherlands brings a lot to the table in terms of novel drug development and innovative biotechnology, and international partnering is expected to gain in importance for the future growth of Dutch life science companies.”
Home to Leiden Bio Science Park, the leading life sciences cluster, the Netherlands biotech and biomedical business sector offers opportunities for both start-ups and established companies including licensing and innovative research and development.
“The core value of Dutch companies is based on our strength to transform excellence in science into commercial success,” said Onno van de Stolpe, CEO of Galapagos. “Partnering is key to the sector. Deals between biotech and big pharma are essential to provide credibility to investors and generate cash flow to fund research. As one of the premier partnering events in the world, BIO-Europe Spring is an important catalyst for forming the collaborations that drive the industry.”
A report published in January 2012 by Life Sciences Health (LSH), the national cluster organization of the Dutch life sciences and health sector, reported 329 companies that employed 24,385 people between 2009 and 2010, with continued growth in the number of companies expected. The cluster also reported the expectation that partnerships or alliances will be a major source of future financial growth for Dutch companies followed by M&A. The report stated that the sector is growing steadily mainly due to an increase in small start-up companies, with large companies (over 250 employees) still responsible for nearly 90% of the total revenue. A copy of the report can be downloaded athttp://www.lifesciencesoutlook.com/.
Partnering opportunities generated by partneringONE®, the leading conference partnering system for the life sciences, are now open. Information on how to create a partnering profile and begin efficiently identifying and requesting meetings with potential collaborators can be found at http://www.ebdgroup.com/bes/partnering/index.php.
The online registration deadline for the conference is March 16, 2012, 13:00 CET, after which all registrations will be handled on site. Information on the conference and registration details can be found online at http://www.ebdgroup.com/bes/registration/index.php
For more information about BIO-Europe Spring, go towww.ebdgroup.com/bes/index.php.
Additional links and information:
Follow BIO-Europe Spring 2012 on Twitter: twitter.com/EBDgroup (hashtag: #BES12)
LinkedIn Event site: http://linkd.in/uA0L0x
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:
EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.
EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com.
As the springtime counterpart to BIO-Europe®, BIO-Europe Spring® continues the tradition of providing life science companies with high caliber partnering opportunities. Featuring EBD Group’s acclaimed partnering system, partneringONE®, the event enables delegates to efficiently identify, meet and get partnerships started with companies across the biotech value chain.
In addition to productive partnering, BIO-Europe Spring offers high level workshops, panels, company presentations, and a lively exhibition. The program features executive level panelists who openly share their insight and opinion on many important industry issues. The company presentation tracks provide a forum for innovative start-ups, established biotech companies, and large and midsize pharma to present information on products, partnering opportunities and corporate strategy.
Combined, these elements create an insightful and productive event that will have you coming back year after year.
BIO-Europe Spring is produced by EBD Group, the leading partnering firm for the global biotechnology industry, with the support of the Biotechnology Industry Organization (BIO).
Follow BIO-Europe Spring 2014 on Twitter: twitter.com/ebdgroup (hashtag: #BES14). Or log on to the BIO-Europe Spring 2014 Discussion Forum on partnering360. The Group is your go-to discussion forum for news and topics related to BIO-Europe Spring.